Adalimumab (Humira) Biosimilars Pipeline Review 2024: A Recombinant Human IgG1 mAb - Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
24. Oktober 2024 09:57 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Adalimumab (Humira) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information on...
Samsung Bioepis’ Fourth Quarter 2024 US Biosimilar Market Report Highlights Challenges and Strategies for Biosimilar Adoption
10. Oktober 2024 08:00 ET
|
Samsung Bioepis
Samsung Bioepis’ Fourth Quarter 2024 US Biosimilar Market Report Highlights Challenges and Strategies for Biosimilar Adoption
Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report
11. Juli 2024 08:00 ET
|
Samsung Bioepis
Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
27. Juni 2024 08:26 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend...
US HUMIRA Market Projected for Extensive Growth by 2032 in Noninfectious Autoimmune Uveitis Sector
28. Februar 2024 11:05 ET
|
Research and Markets
Dublin, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The "US HUMIRA Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering. An insightful analysis...
Global Dupuytren's Disease Research Report 2023: A $5.87 Billion Market by 2030 - Injectable Collagenase Therapies Revolutionize Contracture Management
11. Dezember 2023 09:18 ET
|
Research and Markets
Dublin, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The "Dupuytren's Disease Market Size, Share & Trends Analysis Report By Type (Diagnosis, Treatment), By Disease Type (Type I, Type II), By End-use...
Amgen’s Amjevita Remains the Frontrunner in the US Adalimumab Biosimilars Market, Despite Increased Competition, According to Spherix Global Insights.
14. September 2023 11:37 ET
|
Spherix Global Insights
Exton, Pennsylvania, Sept. 14, 2023 (GLOBE NEWSWIRE) -- This summer ushered in the highly anticipated introduction of a multitude of additional adalimumab biosimilars to the dynamic US immunology...
Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update
11. August 2023 16:05 ET
|
Rani Therapeutics, LLC
- Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three...
Rani Therapeutics to Participate in August Investor Conferences
04. August 2023 16:05 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™
13. Juli 2023 08:30 ET
|
Coherus BioSciences, Inc.
First formal distribution agreement for YUSIMRY™, a biosimilar of Humira®, at $995 per carton (two 40 mg/0.8 mL autoinjectors) representing a discount of more than 85% compared to HumiraInnovative...